1. Caspase-8 promotes scramblase-mediated phosphatidylserine exposure and fusion of osteoclast precursors.
- Author
-
Krishnacoumar, Brenda, Stenzel, Martin, Garibagaoglu, Hilal, Omata, Yasunori, Sworn, Rachel L., Hofmann, Thea, Ipseiz, Natacha, Czubala, Magdalena A., Steffen, Ulrike, Maccataio, Antonio, Stoll, Cornelia, Böhm, Christina, Herrmann, Martin, Uderhardt, Stefan, Jenkins, Robert H., Taylor, Philip R., Grüneboom, Anika, Zaiss, Mario M., Schett, Georg, and Krönke, Gerhard
- Subjects
BONE resorption ,BONE remodeling ,CASPASES ,RNA analysis ,PHOSPHATIDYLSERINES - Abstract
Efficient cellular fusion of mononuclear precursors is the prerequisite for the generation of fully functional multinucleated bone-resorbing osteoclasts. However, the exact molecular factors and mechanisms controlling osteoclast fusion remain incompletely understood. Here we identify RANKL-mediated activation of caspase-8 as early key event during osteoclast fusion. Single cell RNA sequencing-based analyses suggested that activation of parts of the apoptotic machinery accompanied the differentiation of osteoclast precursors into mature multinucleated osteoclasts. A subsequent characterization of osteoclast precursors confirmed that RANKL-mediated activation of caspase-8 promoted the non-apoptotic cleavage and activation of downstream effector caspases that translocated to the plasma membrane where they triggered activation of the phospholipid scramblase Xkr8. Xkr8-mediated exposure of phosphatidylserine, in turn, aided cellular fusion of osteoclast precursors and thereby allowed generation of functional multinucleated osteoclast syncytia and initiation of bone resorption. Pharmacological blockage or genetic deletion of caspase-8 accordingly interfered with fusion of osteoclasts and bone resorption resulting in increased bone mass in mice carrying a conditional deletion of caspase-8 in mononuclear osteoclast precursors. These data identify a novel pathway controlling osteoclast biology and bone turnover with the potential to serve as target for therapeutic intervention during diseases characterized by pathologic osteoclast-mediated bone loss. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF